The use of green fluorescent protein as a marker for Brucella vaccines

Vaccine

Volumn 29, Issue 3, 2011, Pages 577-582

  Chacón Díaz, Carlos ^a,b   Muñoz Rodríguez, Melissa ^a   Barquero Calvo, Elías ^a   Guzmán Verri, Caterina ^a   Chaves Olarte, Esteban ^a,b   Grilló, María Jesús ^c   Moreno, Edgardo ^a,b  

^a UNIVERSIDAD NACIONAL   (Costa Rica)

^b UNIVERSIDAD DE COSTA RICA   (Costa Rica)

^c CSIC   (Spain)

Author keywords

Brucella; Brucellosis; Diagnostic tests; ELISA; GFP; Rev1; S19; Vaccines

Indexed keywords

BIOCHEMICAL MARKER; BRUCELLA VACCINE; GREEN FLUORESCENT PROTEIN; LIPOPOLYSACCHARIDE;

ANTIBODY RESPONSE; ARTICLE; BACTERIAL STRAIN; BACTERIAL VIRULENCE; BRUCELLA ABORTUS; BRUCELLOSIS; DIAGNOSTIC TEST; DIAGNOSTIC TEST ACCURACY STUDY; ENZYME IMMUNOASSAY; EX VIVO STUDY; EXPERIMENTAL MODEL; FEMALE; IMMUNE RESPONSE; IN VIVO STUDY; MICROSCOPY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; ULTRAVIOLET RADIATION;

ANIMALS; BRUCELLA ABORTUS; BRUCELLA VACCINE; BRUCELLOSIS; DIAGNOSIS, DIFFERENTIAL; DISEASE MODELS, ANIMAL; FEMALE; GREEN FLUORESCENT PROTEINS; MICE; VACCINES, MARKER; ZOONOSES;

EID: 78650518402     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2010.09.109     Document Type: Article

References (52)

1. Moreno E., Moriyón I. The genus Brucella. The Prokaryotes 2006, vol. 5:315-456. Springer-Verlag, New York.
2. Nicoletti P. Vaccination against Brucella. Adv Biotechnol Processes 1990, 13:147-168.
3. Office International des Épizooties Bovine brucellosis. Manual of diagnostic tests and vaccines for terrestrial animals, vol. 2 2009, 1-35. OIE, Paris.
4. Nicoletti P. Prevention of animal brucellosis: the role of the veterinary services. Prevention of brucellosis in Mediterranean countries 1992, 113-116. International Center for Advanced Mediterranean Agronomic Studies, Pudoc, Scientific Publishers, Wageningen, Netherlands. M. Plommet (Ed.).
5. Elzer P.H., Enright F.M., Colby L., Hagius S.D., Walker J.V., Fatemi M.B., et al. Protection against infection and abortion induced by virulent challenge exposure after oral vaccination of cattle with Brucella abortus strain RB51. Am J Vet Res 1998, 59(12):1575-1578.
6. Schurig G.G., Sriranganathan N., Corbel M.J. Brucellosis vaccines: past, present and future. Vet Microbiol 2002, 90(1-4):479-496.
7. Díaz-Aparicio E., Aragón V., Marín C., Alonso B., Font M., Moreno E., et al. Comparative analysis of Brucella serotype A and M and Yersinia enterocolitica O:9 polysaccharides for serological diagnosis of brucellosis in cattle, sheep, and goats. J Clin Microbiol 1993, 31(12):3136-3141.
8. Plommet M. Progres recents en immunisation contre l'infection a immunisation chez les bovins. Prev Vet Med 1984, 2(1-4):205-214.
9. Gall D., Colling A., Marino O., Moreno E., Nielsen K., Pérez B., et al. Enzyme immunoassays for serological diagnosis of bovine brucellosis: a trial in Latin America. Clin Diagn Lab Immunol 1998, 5(5):654-661.
10. Moriyón I., Grilló M.J., Monreal D., González D., Marín C., López-Goñi I., et al. Rough vaccines in animal brucellosis: structural and genetic basis and present status. Vet Res 2004, 35(1):1-38.
11. González D., Grilló M.J., De Miguel M.J., Ali T., Arce-Gorvel V., Delrue R.M., et al. Brucellosis vaccines: assessment of Brucella melitensis lipopolysaccharide rough mutants defective in core and O-polysaccharide synthesis and export. PLoS One 2008, 3(7):e2760.
12. Blasco J. A review of the use of B. melitensis Rev 1 vaccine in adult sheep and goats. Prev Vet Med 1997, 31(3-4):275-283.
13. Fensterbank R., Plommet M. Vaccination against bovine brucellosis with a low dose of strain 19 administrated by the conjunctival route IV. Comparison between two methods of vaccination. Ann Res Vet 1979, 10(1):131-139.
14. Winter A.J., Schurig G.G., Boyle S.M., Sriranganathan N., Bevins J.S., Enright F.M., et al. Protection of Balb/c mice against homologous and heterologous species of Brucella by rough strain vaccines derived from Brucella melitensis and Brucella suis biovar 4. Am J Vet Res 1996, 57(5):677-683.
15. Monreal D., Grilló M.J., González D., Marín C.M., De Miguel M.J., López-Goñi I., et al. Characterization of Brucella abortus O-polysaccharide and core lipopolysaccharide mutants and demonstration that a complete core is required for rough vaccines to be efficient against Brucella abortus and Brucella ovis in the mouse model. Infect Immun 2003, 71(6):3261-3271.
16. Barrio M.B., Grilló M.J., Muñoz P.M., Jacques I., González D., De Miguel M.J., et al. Rough mutants defective in core and O-polysaccharide synthesis and export induce antibodies reacting in an indirect ELISA with smooth lipopolysaccharide and are less effective than Rev 1 vaccine against Brucella melitensis infection of sheep. Vaccine 2009, 27:1741-1749.
17. Blasco J.M., Moriyón I. Protection of Brucella abortus RB51 revaccinated cows. Comp Immunol Microbiol Infect Dis 2005, 28(5-6):371-373.
18. Herrera-López E., Suárez-Güemes F., Hernández-Andrade L., Córdova-López D., Díaz-Aparicio E. Epidemiological study of brucellosis in cattle, immunized with Brucella abortus RB51 vaccine in endemic zones. Vaccine 2010, [Epub ahead of print].
19. Moreno E. Brucellosis in Central America. Vet Microbiol 2002, 90(1-4):31-38.
20. Blasco J.M., Moriyón I. Eradication of bovine brucellosis in the Azores Portugal: outcome of a 5-year programme (2002-2007) based on test-and-slaughter and RB51 vaccination. Prev Vet Med 2010, 94(1-2):154-157.
21. Boschiroli M.L., Cravero S.L., Arese A.I., Campos E., Rossetti O.L. Protection against infection in mice vaccinated with a Brucella abortus mutant. Infect Immun 1997, 65(2):798-800.
22. Fiorentino M.A., Campos E., Cravero S., Arese A., Paolicchi F., Campero C., et al. Protection levels in vaccinated heifers with experimental vaccines Brucella abortus M1-luc and INTA 2. Vet Microbiol 2008, 132(3-4):302-311.
23. Guilloteau L.A., Laroucau K., Olivier M., Grilló M.J., Marín C.M., Verger J.M., et al. Residual virulence and immunogenicity of CGV26 and CGV2631 B. melitensis Rev. 1 deletion mutant strains in sheep after subcutaneous or conjunctival vaccination. Vaccine 2006, 24(17):3461-3468.
24. Cloeckaert A., Debbarh H.S.A., Vizcaíno N., Saman E., Dubray G., Zygmunt M.S. Cloning, nucleotide sequence, and expression of the Brucella melitensis bp26 gene coding for a protein immunogenic in infected sheep. FEMS Microbiol Lett 1996, 140(2-3):139-144.
25. Debbarh H.S.A., Zygmunt M.S., Dubray G., Cloeckaert A. Competitive Enzyme-linked immunosorbent assay using monoclonal antibodies to the B. melitensis BP26 protein to evaluate antibody responses in infected and B. melitensis Rev.1 vaccinated sheep. Vet Microbiol 1996, 53(3-4):325-337.
26. Rossetti O.L., Arese A.I., Boschiroli M.L., Cravero S.L. Cloning of Brucella abortus gene and characterization of expressed 26-kilodalton periplasmic protein: potential use for diagnosis. J Clin Microbiol 1996, 34(1):165-169.
27. Zygmunt M.S., Baucheron S., Vizcaino N., Bowden R.A., Cloeckaert A. Single-step purification and evaluation of recombinant BP26 protein for serological diagnosis of Brucella ovis infection in rams. Vet Microbiol 2002, 87(3):213-220.
28. Grilló M.J., Manterola L., de Miguel M.J., Muñoz P.M., Blasco J.M., Moriyón I., et al. Increases of efficacy as vaccine against Brucella abortus infection in mice by simultaneous inoculation with avirulent smooth bvrS/bvrR and rough wbkA mutants. Vaccine 2006, 24(15):2910-2916.
29. Jacques I., Verger J.M., Laroucau K., Grayon M., Vizcaino N., Peix A., et al. Immunological responses and protective efficacy against Brucella melitensis induced by bp26 and omp31 B. melitensis Rev 1 deletion mutants in sheep. Vaccine 2007, 25(5):794-805.
30. Mukherjee F., Jain J., Grilló M.J., Blasco J.M., Nair M. Evaluation of Brucella abortus S19 vaccine strains by bacteriological tests, molecular analysis of ery loci and virulence in BALB/c mice. Biologicals 2005, 33(3):153-160.
31. Celli J., de Chastellier C., Franchini D.M., Pizarro-Cerda J., Moreno E., Gorvel J.P. Brucella evades macrophage killing via VirB-dependent sustained interactions with the endoplasmic reticulum. J Exp Med 2003, 198(4):545-556.
32. Kovach M.E., Elzer P.H., Hill D.S., Robertson G.T., Farris M.A., Roop R.M., et al. Four new derivatives of the broad-host-range cloning vector pBBR1MCS, carrying different antibiotic-resistance cassettes. Gene 1995, 166(1):175-176.
33. Guzmán-Verri C., Chaves-Olarte E., von Eichel-Streiber C., López-Goñi I., Thelestam M., Arvidson S., et al. GTPases of the Rho subfamily are required for Brucella abortus internalization in nonprofessional phagocytes: direct activation of Cdc42. J Biol Chem 2001, 276(48):44435-44443.
34. Pizarro-Cerdá J., Moreno E., Sanguedolce V., Mege J.L., Gorvel J.P. Virulent Brucella abortus prevents lysosome fusion and is distributed within autophagosome-like compartments. Infect Immun 1998, 66(5):2387-2392.
35. Grilló M.J., Bosseray N., Blasco J.M. In vitro markers and biological activity in mice of seed lot strains and commercial Brucella melitensis Rev 1 and Brucella abortus B19 vaccines. Biologicals 2000, 28(2):119-127.
36. Harlow E., Lane D. Antibodies: a laboratory manual 1988, Cold Spring Harbor, Laboratory, New York.
37. Hudson L., Hay F.C. Practical immunology 1976, Blackwell Scientific, Oxford.
38. Crowther J. Methods in molecular biology. The ELISA guidebook 2001, vol. 149. Human Press Inc, New Jersey.
39. Weiss D.S., Takeda K., Akira S., Zychlinsky A., Moreno E. MyD88, but not toll-like receptors 4 and 2, is required for efficient clearance of Brucella abortus. Infect Immun 2005, 73(8):5137-5143.
40. Verger J.M., Grayon M., Chaslus-Dancla E., Meurisse M., Lafont J.P. Conjugative transfer and in vitro/in vivo stability of the broad-host-range IncP R751 plasmid in Brucella spp. Plasmid 1993, 29(2):142-146.
41. Bosseray N., Plommet M. Brucella suis S2, Brucella melitensis Rev. 1 and Brucella abortus S19 living vaccines: residual virulence and immunity induced against three Brucella species challenge strains in mice. Vaccine 1990, 8(5):462-468.
42. Boschiroli L., Cravero S., Arese A., Rossetti O.L. Construcción y caracterización de una mutante de Brucella abortus por inactivación de un gen que codifica una proteína de 26kDa. Arch Med Vet 1995, 27(SI):103-111.
43. Cloeckaert A., Jacques I., Grilló M.J., Marín C.M., Grayon M., Blasco J.M., et al. Development and evaluation as vaccines in mice of Brucella melitensis Rev.1 single and double deletion mutants of the bp26 and omp31 genes coding for antigens of diagnostic significance in ovine brucellosis. Vaccine 2004, 22(21-22):2827-2835.
44. Grilló M.J., Marín C.M., Barberán M., de Miguel M.J., Laroucau K., Jacques I., et al. Efficacy of bp26 and bp26/omp31 B. melitensis Rev.1 deletion mutants against Brucella ovis in rams. Vaccine 2009, 27(2):187-191.
45. Cloeckaert A., Zygmunt M.S., Guilloteau L.A. Brucella abortus vaccine strain RB51 produces low levels of M-like O-antigen. Vaccine 2002, 20(13-14):1820-1822.
46. Leal-Hernandez M., Díaz-Aparicio E., Pérez R., Andrade L.H., Arellano-Reynoso B., Alfonseca E., et al. Protection of Brucella abortus RB51 revaccinated cows, introduced in a herd with active brucellosis, with presence of atypical humoral response. Comp Immunol Microbiol Infect Dis 2005, 28(1):63-70.
47. Nicoletti P. Prevalence and persistence of Brucella abortus strain 19 infections and prevalence of other biotypes in vaccinated adult dairy cattle. J Am Vet Med Assoc 1981, 178(2):143-145.
48. Yazdi H.S., Kafi M., Haghkhah M., Tamadon A., Behroozikhah A.M., Ghane M. Abortions in pregnant dairy cows after vaccination with Brucella abortus strain RB51. Vet Rec 2009, 165(19):570-571.
49. Prasher D.C., Eckenrode V.K., Ward W.W., Prendergast F.G., Cormier M.J. Primary structure of the Aequorea victoria green-fluorescent protein. Gene 1992, 111(2):229-233.
50. Walsh E.P., Baron M.D., Anderson J., Barrett T. Development of a genetically marked recombinant rinderpest vaccine expressing green fluorescent protein. J Gen Virol 2000, 81(Pt 3):709-718.
51. Walsh E.P., Baron M.D., Rennie L.F., Monaghan P., Anderson J., Barrett T. Recombinant rinderpest vaccines expressing membrane-anchored proteins as genetic markers: evidence of exclusion of marker protein from the virus envelope. J Virol 2000, 74(21):10165-10175.
52. Crasta O.R., Folkerts O., Fei Z., Mane S.P., Evans C., Martino-Catt S., et al. Genome sequence of Brucella abortus vaccine strain S19 compared to virulent strains yields candidate virulence genes. PLoS One 2008, 3(5):e2193.